Amendment to the Claims

1-7 (Canceled)

8 (Original) A pharmaceutical composition comprising a protein useful for treating a lysosomal storage disorder other than Fabry disease that is selectively imported into macrophages when administered to a subject and a pharmaceutically acceptable carrier, wherein said protein is produced in an insect cell culture.

9 (Previously presented) The composition of claim 8 wherein said lysosomal storage disorder is Galactosialidosis.

10 (Previously presented) The composition of claim 8 wherein said protein is protective protein/cathepsin A (PPCA).

11 (Original) The composition of claim 8 wherein said insect cell culture comprises cells derived from the species selected from the group consisting of *Spodoptera frugiperda* and *Tricophusia ni*.

12 (Original) The composition of claim 11 wherein said cells are *Spodoptera frugiperda* Sf9 cells.

13 (Original) The composition of claim 8 wherein said protein is produced in the cell culture using a baculovirus expression system.

14-20 (Canceled)

21 (New) The composition of claim 8 wherein said lysosomal storage disorder is selected from the group consisting of Pompe Disease, GM1 gangliosidosis, Tay-Sachs disease, GM2 gangliosialidosis: AB Variant, Sandhoff Disease, Gaucher Disease, Krabbe Disease, Niemann-Pick Types A-D, Farber Disease, Wolman Disease, Cholesterol Ester Storage Disease, Hurler Syndrome, Scheie Syndrome, Hurler-Scheie, Hunter Syndrome, Sanfilippo A-D, Morquio A-B, Maroteaux-Lamy, Sly Syndrome, Metachromatic Leukodystrophy, Multiple Sulfatase Deficiency, Sialidosis, I-Cell Disease, Pseudo-Hurler Polydistrophy, Mucolipidosis IV, α-Mannosidosis, β- Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Galactosialidosis, Schindler Disease, Cystinosis, Salla Disease, Infantile Sialic Acid Storage Disorder, Batten Disease, Infantile Neuronal Ceroid Lipofuscinosis, and Prosaposin.

22. (New) The composition of claim 8 wherein said protein is selected from the group consisting of acid α-1,4 glucosidase, acid α-1,6 glucosidase, β-galactosidase, β-hexosaminidase A, GM_2 Activator Protein, β-hexosaminidase A, β-hexosaminidase B, glucocerebrosidase, β-glucosidase, galactosylcerebrosidase, acid sphingomyelinase, acid ceramidase, acid lipase, α-L-iduronidase, iduronate sulfatase, α-N-acetylglucosaminidase, acetyl-CoA-glucosaminide acetyltransferase, N-acetylglucosamine-6-sulfatase, galactosamine-6-sulfatase, arylsuylfatase B, β-glucuronidase, arylsulfatase A, arylsulfatase C, α-Neuraminidase, UDP GlcNAc:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase, neuraminidase, α-mannosidase, β-mannosidase, α-L-fucosidase, N-aspartyl-β-glucosaminidase, protective protein/cathepsin A (PPCA), α-N-acetyl-galactosaminidase, cystine transport protein, sialic acid transport protein, palmitoyl-protein thioesterase, and Saposins A-D.

23 (New) The composition of claim 21 wherein said lysosomal storage disorder is Sialidosis.

24 (New) The composition of claim 22 wherein said protein is α-Neuraminidase.